In each case, 2 patients (4.8%) harbored CNV in all 3 exons of EGFR and FGFR1, and only one patient (2.4%) had CNV in both exons of TOP2A, suggesting that the whole genes were possibly amplified in the primary tumor. The gene discussed is FGFR1; the disease is neoplasm.